Science 37 Holdings, Inc. (SNCE)

Science 37 Holdings, Inc. (SNCE) Healthcare & Pipeline Overview

Science 37 Holdings, Inc. offers a technology platform for decentralized clinical trials, connecting patients, investigators, and sponsors. The platform aims to streamline workflows, centralize data, and enhance clinical research efficiency, serving pharmaceutical companies, CROs, and academic institutions within the healthcare information services sector.

What Is the Investment Thesis for SNCE?

Science 37 Holdings, Inc. operates in the growing decentralized clinical trial (DCT) market, offering a platform that streamlines clinical research processes. With a market capitalization of $0.03 billion and a negative P/E ratio of -13.07, the company is currently unprofitable, indicated by a profit margin of -72.7%. However, the increasing adoption of DCTs, driven by the need for faster and more cost-effective clinical trials, presents a significant growth opportunity. The company's gross margin of 22.6% suggests potential for improved profitability as the platform scales. Key value drivers include expanding its customer base among pharmaceutical companies and CROs, enhancing its platform capabilities, and demonstrating improved clinical trial efficiency and patient engagement. The company's beta of 0.56 indicates lower volatility compared to the market.

Based on FMP financials and quantitative analysis

SNCE Key Highlights

• Market capitalization of $0.03 billion, reflecting its current valuation in the market.
• Negative P/E ratio of -13.07, indicating the company is not currently profitable.
• Profit margin of -72.7%, highlighting significant losses relative to revenue.
• Gross margin of 22.6%, suggesting potential for improved profitability with scale.
• Beta of 0.56, indicating lower volatility compared to the overall market.

Who Are SNCE's Competitors?

Who Are SNCE's Competitors?

SNCE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SNCE's Key Strengths?

• Technology platform designed for decentralized clinical trials.
• Established network of patients and investigators.
• Extensive configuration options for various study phases.
• Proprietary data and analytics capabilities.

What Are SNCE's Weaknesses?

• Negative profitability and high operating losses.
• Relatively small market capitalization.
• Dependence on adoption of decentralized trials.
• Limited brand recognition compared to larger CROs.

What Could Drive SNCE Stock Higher?

• Increasing adoption of decentralized clinical trials by pharmaceutical companies and CROs.
• Strategic partnerships with key industry players to expand market reach.
• Potential regulatory approvals or guidelines supporting decentralized trials.
• Launch of new platform features and capabilities to enhance trial efficiency.
• Positive clinical trial results demonstrating the effectiveness of the Science 37 platform.

What Are the Key Risks for SNCE?

• Competition from larger and more established CROs and technology providers.
• Regulatory changes that could negatively impact decentralized clinical trials.
• Data security and privacy breaches compromising patient data.
• Economic downturn leading to reduced research funding and slower adoption of new technologies.
• Failure to achieve profitability and maintain sufficient cash flow.

What Are the Growth Opportunities for SNCE?

• Expansion of Decentralized Clinical Trial (DCT) Adoption: The increasing acceptance and adoption of DCTs within the pharmaceutical and biotech industries present a significant growth opportunity for Science 37. As regulatory bodies become more supportive of DCTs and the benefits of increased patient access and reduced costs become more apparent, the demand for Science 37's platform is expected to rise. The global DCT market is projected to reach billions of dollars in the coming years, offering substantial revenue potential for Science 37.
• Strategic Partnerships with Pharmaceutical Companies and CROs: Forming strategic partnerships with large pharmaceutical companies and contract research organizations (CROs) can provide Science 37 with access to a broader customer base and increased market penetration. These partnerships can involve integrating Science 37's platform into the CRO's service offerings or collaborating on specific clinical trials. Such collaborations can lead to long-term contracts and recurring revenue streams, strengthening Science 37's financial position.
• Enhancement of Platform Capabilities and Features: Continuous innovation and enhancement of Science 37's technology platform are crucial for maintaining a competitive edge and attracting new customers. This includes incorporating advanced data analytics, artificial intelligence (AI), and machine learning (ML) capabilities to improve trial efficiency, patient engagement, and data quality. By offering cutting-edge features, Science 37 can differentiate itself from competitors and capture a larger share of the DCT market.
• Geographic Expansion into Untapped Markets: Expanding its geographic footprint into new and emerging markets represents another growth opportunity for Science 37. Many regions around the world are experiencing increasing demand for clinical trials, driven by factors such as aging populations, rising healthcare costs, and the prevalence of chronic diseases. By establishing a presence in these markets, Science 37 can tap into new revenue streams and diversify its customer base.
• Integration of Real-World Data (RWD) and Real-World Evidence (RWE): Integrating real-world data (RWD) and real-world evidence (RWE) into its platform can provide Science 37 with a significant competitive advantage. RWD and RWE can be used to improve trial design, patient selection, and outcome measurement. By offering a platform that seamlessly integrates RWD and RWE, Science 37 can attract customers who are seeking to leverage these data sources to accelerate drug development and improve patient outcomes.

What Opportunities Does SNCE Have?

• Increasing adoption of decentralized clinical trials.
• Strategic partnerships with pharmaceutical companies and CROs.
• Geographic expansion into emerging markets.
• Integration of real-world data and evidence.

What Threats Does SNCE Face?

• Competition from established CROs and technology providers.
• Regulatory changes impacting decentralized trials.
• Data security and privacy concerns.
• Economic downturn affecting research funding.

What Are SNCE's Competitive Advantages?

• Proprietary technology platform designed specifically for decentralized clinical trials.
• Established network of patient communities, telemedicine investigators, and mobile nurses.
• Extensive configuration options to support various phases of clinical studies and indications.
• Data network effects as more trials are run on the platform.

What Does SNCE Do?

Founded in 2014 and headquartered in Research Triangle Park, North Carolina, Science 37 Holdings, Inc. is focused on revolutionizing clinical trials through technology. Recognizing the limitations of traditional clinical trial models, the company developed a platform to enable decentralized or 'agile' clinical trials. This platform brings together all stakeholders, including patients, trial investigators, nurses, coordinators, and sponsors, facilitating a more efficient and patient-centric approach to research. Science 37's platform supports various phases of clinical studies and indications, offering extensive configuration options to meet diverse research needs. The company's core offering is its proprietary hosted technology platform, which it licenses to life science institutions. This platform is complemented by specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices, all designed to orchestrate agile clinical trials. Science 37 serves a diverse clientele, including large and mid-sized pharmaceutical companies, contract research organizations (CROs), academic institutions, and biotech companies, all seeking to modernize their clinical research processes.

What Products and Services Does SNCE Offer?

• Provide a technology platform for decentralized clinical trials.
• Connect patients, investigators, nurses, coordinators, and sponsors.
• Enable agile and digital approaches to clinical research.
• Power workflows and centralize evidence generation.
• Harmonize data from various sources.
• Offer specialized networks of patient communities and telemedicine investigators.
• Provide connected devices for remote monitoring.
• License its proprietary hosted technology platform to life science institutions.

How Does SNCE Make Money?

• Licensing its proprietary hosted technology platform to life science institutions.
• Providing access to specialized networks of patient communities, telemedicine investigators, and mobile nurses.
• Offering extensive configuration options to support various phases of clinical studies and indications.

What Industry Does SNCE Operate In?

Science 37 Holdings, Inc. operates within the healthcare information services sector, which is experiencing growth driven by the increasing adoption of digital health technologies and decentralized clinical trials. The market is competitive, with companies like AKLI (Akili Interactive Labs, Inc.), HEXO (HEXO Corp.), ISO (IsoPlexis Corporation), LIANY (LianBio), and RAD (Rite Aid Corporation) also vying for market share. The shift towards decentralized trials is fueled by the need for faster, more cost-effective, and patient-centric clinical research. Science 37 aims to capitalize on this trend by offering a comprehensive technology platform that streamlines the clinical trial process and improves patient engagement.

Who Are SNCE's Key Customers?

• Large and mid-sized pharmaceutical companies.
• Contract research organizations (CROs).
• Academic institutions.
• Biotech companies.

SNCE Financials

SNCE Latest News

No recent news available for SNCE.

SNCE Analyst Consensus

SNCE MoonshotScore

Science 37 Holdings, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources